QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-wave-life-sciences-showcases-wve-007-data-demonstrating-fat-loss-with-muscle-preservation-in-preclinical-models

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for ...

 wave-life-sciences-released-data-from-its-inlight-clinical-trial-of-wve-007-showing-up-to-85-mean-reduction-in-activin-e-levels-one-month-after-a-single-doseexceeding-reductions-linked-to-weight-loss-in-preclinical-studies

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, excee...

 clear-street-initiates-coverage-on-wave-life-sciences-with-buy-rating-announces-price-target-of-22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating and announces Pric...

 wells-fargo-maintains-overweight-on-wave-life-sciences-lowers-price-target-to-18

Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from...

 why-is-gsk-partner-wave-life-sciences-stock-trading-lower-on-wednesday

Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production a...

 hc-wainwright--co-reiterates-buy-on-wave-life-sciences-maintains-22-price-target

HC Wainwright & Co. analyst Andrew S. Fein reiterates WAVE Life Sciences (NASDAQ:WVE) with a Buy and maintains $22 price...

 wave-life-sciences-announces-data-from-200-mg-single-and-multidose-and-400-mg-single-dose-cohorts-of-ongoing-phase-1b2a-restoraation-2-study-evaluating-wve-006-as-treatment-for-aatd

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases followi...

 canaccord-genuity-initiates-coverage-on-wave-life-sciences-with-buy-rating-announces-price-target-of-19

Canaccord Genuity analyst Whitney Ijem initiates coverage on WAVE Life Sciences (NASDAQ:WVE) with a Buy rating and announces...

 wells-fargo-maintains-overweight-on-wave-life-sciences-lowers-price-target-to-21

Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight and lowers the price target from...

 wave-life-sciences-q2-eps-031-misses-029-estimate-sales-8699m-miss-11245m-estimate

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION